| Nov 6 |
Gilead Sciences Announces Third Quarter 2024 Financial Results
|
| Nov 6 |
Top 20 biopharmas’ market cap rises 2% in Q3 2024 amid flurry of drug approvals
|
| Nov 5 |
Arcus says Gilead-partnered cancer therapy cut death risk by 36%
|
| Nov 5 |
Gilead Sciences Q3 Earnings Preview: Pipeline shows potential despite near-term challenges
|
| Nov 5 |
Kite to Highlight Industry-Leading CAR T-Cell Therapy Portfolio at ASH 2024, Including Positive Survival Outcomes in Both Clinical Trials and the Real-World
|
| Nov 5 |
Gilead Sciences's Earnings: A Preview
|
| Nov 4 |
Is Gilead Sciences, Inc. (GILD) the Best Pharma Stock to Buy Right Now?
|
| Nov 3 |
Wall Street Week Ahead
|
| Nov 1 |
Stocks to watch next week: Berkshire Hathaway, Super Micro, Novo Nordisk, Vistry and M&S
|
| Nov 1 |
Ahead of Gilead (GILD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
|
